Success at Glaxo’s HIV Unit May Mean Having to Call It Quits

HIV drugs are proving to be so effective in containing the virus that GlaxoSmithKline Plc foresees a time, a decade away, when its most profitable business unit may no longer have a purpose.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.